Read more
Informationen zum Autor Dr Corey Siegel, Director, Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon, NH, USA. Dr Peter Irving, Consultant Gastroenterologist, Guy's and St Thomas' Hospital London. Prof David Rampton, Professor of Clinical Gastroenterology, Barts and The London, London. Prof Fergus Shanahan, Professor and Chairman, Department of Medicine/Director of Alimentary Pharmabiotic Centre, University College Cork, Ireland. Klappentext The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice.In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking.Each of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments.This book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, colorectal surgeons, pathologists, radiologists, specialist nurses, pharmacists, dieticians and counselors. Zusammenfassung Unlike other books on IBD which focus on systematic diagnosis, treatment plans, etc. , this book addresses the key dilemmas that specialists face every day, providing a clinically focused analysis of controversial areas of IBD management, including emerging treatment therapies, surgical issues, and infection. Inhaltsverzeichnis List of Contributors. Preface. Part 1: Genes and Phenotype in IBD. 1 Which will take us further in IBD - study of coding variation or epigenetics? ( Miles Parkes ). 2 IBD in different ethnic groups: same or different? ( Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger ). Part 2: Bugs and IBD - good, bad or indifferent? 3 How does the risk of infection influence management of IBD around the world? ( Kiran K. Peddi and Ian Craig Lawrance ). 4 Travelling with IBD ( Ing Shian Soon and Gilaad Kaplan ). 5 What to do about hepatitis B and hepatitis C in patients with IBD ( Morven Cunningham and Graham R. Foster ). 6 CMV in IBD - passenger or pathogen? ( Ahmed Kandiel & Bret Lashner ). 7 Clostridium difficile in IBD: Impact, Prevention and Treatment ( Ashwin N. Ananthakrishnan and David G. Binion ). 8 Pre- and synbiotics: placebo or panacea ( James O. Lindsay ). 9 Worms - light at the end of their burrow? ( John Leung and Joel V. Weinstock ). 10 Do we really need to vaccinate all patients with IBD? ( Gauree Gupta and Gil Y. Melmed ). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel? ( Richard B. Gearry, Andrew S. Day ). 12 Radiation exposure in IBD: how do we minimize the dangers? ( Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher ). 13 Surveillance colonoscopy in UC - what's the best way to do it? ( Matt Rutter ). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride forward? (L. Campbell Levy). 15 Do 5ASAs prevent cancer? ( Richard Logan and Venkataraman Subramanian ). 16 Why do we still use 5-ASAs in Crohns disease? ( Stephen Hanauer, Henit Yanai, Emma Calabrese ). Steroids. 17 Steroids in Crohn's disease: do the benefits outweigh the...
